摘要
Use of atypical antipsychotics （AAPs） in child/adolescent psychiatry （CAP） population is rife to address a wide array of indications. Apart from the Food and Drug Administration approval in schizophrenia, bipolar mood disorders, irritability in autism spectrum disorder, and Tourette＇s syndrome, AAPs are commonly prescribed off-label for aggression in intellectual disability or attention-deficit/hyperactivity disorder, augmentation in depression and obsessive-compulsive disorder.
Use of atypical antipsychotics （AAPs） in child/adolescent psychiatry （CAP） population is rife to address a wide array of indications. Apart from the Food and Drug Administration approval in schizophrenia, bipolar mood disorders, irritability in autism spectrum disorder, and Tourette＇s syndrome, AAPs are commonly prescribed off-label for aggression in intellectual disability or attention-deficit/hyperactivity disorder, augmentation in depression and obsessive-compulsive disorder.
